Health ❯ Healthcare ❯ Clinical Trials ❯ Patient Outcomes
Retrospective AI analysis of AMARANTH data revealed a 46% slower decline in slow-progressors treated with lanabecestat, prompting NHS Innovation East England to fund clinical integration.